News
World Economic Forum initiative brings food-as-medicine solutions to Boston
The cohort includes four Boston-based companies focused on medically tailored groceries, meal kits and farm-to-home delivery. … […]
Month: July 2026
News
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced… … […]
News
French drugmaker commits to Cambridge headquarters years ahead of schedule
The French drugmaker’s lease extension covers both buildings at Cambridge Crossing, where it consolidated about 2,500 employees from nine Greater Boston sites in 2022. … […]
News
Thymmune Therapeutics acquired by Maryland biotech for $140M
The deal brings Thymmune’s thymus cell therapy platform to a company known for lung disease treatments and pig-to-human transplant research. The acquisition closed Thursday. … […]
News
Why are some bacterial genes high in purines?
In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents. … […]
News
PureTech spinout lands $180M from investors including RA Capital, Leaps by Bayer
The Boston company is a spinout of PureTech Health, which has produced companies like Karuna Therapeutics and Seaport Therapeutics. … […]
News
Cambridge Health Alliance reopens birth center after six-year closure
The reopening represents a rare expansion as maternity wards across Massachusetts have shuttered in recent years. … […]
News
Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
Zenocutuzumab offers meaningful and durable antitumor activity, substantially reduced toxicity and no treatment‑limiting safety concerns, distinguishing it favorably from existing standards of care LEXINGTON, Mass., July 2, 2026 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private,… … […]
News
Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
MILFORD, Mass., July 2, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters’ Investor Relations website at… … […]
News
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda’s therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ — Insilico Medicine (“Insilico” HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic… … […]
